| Similar Articles |
|---|
 |
Chemistry World
March 29, 2010
Anna Lewcock |
Drug adviser quits over science advice rules The resignation of a sixth scientist from the UK government's drugs advisory body could trigger more departures and calls into further question the council's ability to offer vital scientific advice.   |
Chemistry World
July 9, 2015
Maria Burke |
UK 'legal highs' bill under fire from scientific community Calls are growing from the scientific community for home secretary Theresa May to amend the psychoactive substances bill. |
Chemistry World
November 6, 2009
Anna Lewcock |
Loss of senior chemist throws further doubt on future of UK drugs council David Nutt has insisted he has 'right on his side' following his unceremonious dismissal as chair of the UK Home Office Advisory Council on the Misuse of Drugs. |
Chemistry World
June 8, 2015
Maria Burke |
Warnings that proposed UK blanket ban on 'legal highs' casts net too wide Some legal experts and scientists are warning that a proposed blanket ban on so-called 'legal highs' won't tackle the problem and may well hold back research into areas such as neuroscience. |
Search Engine Watch
May 18, 2010
Matthew Ncube |
Tracking Search Habits: The Mephedrone Ban Are Brits kicking the habit, or on the verge of getting hooked? Drilling down to see what the search data tells us. |
Chemistry World
June 4, 2013
Maria Burke |
'Legal high' production gathers pace New designer drugs are popping up in Europe at an unprecedented rate, sometimes on the illicit drug market and sometimes as 'legal' alternatives to controlled drugs, according to the latest report by the EU drugs agency. |
Chemistry World
June 24, 2015
Patrick Walter |
Legal in theory Governments around the world are faced with the particularly tricky problem of what they should do about 'legal highs'. |
Chemistry World
November 11, 2009
Anna Lewcock |
Three more scientists quit drugs council Three more members of the UK government's drugs advisory council have resigned, including renowned chemist Simon Campbell. |
Chemistry World
May 29, 2015
Emma Stoye |
UK launches universal ban on legal highs New laws banning the sale and distribution of all legal highs -- or new psychoactive substances -- have been drafted by the UK government. |
Chemistry World
July 2009
Derek Lowe |
Column: In the pipeline The author wonders where we'd be without the formulation chemists |
The Motley Fool
March 20, 2007
Brian Lawler |
Smart Move by Abbott? Abbott takes a drastic measure to make a point about its patents. Thailand's actions offer a good warning of what can happen when governments try to intervene too much in existing markets. |
Chemistry World
August 2009
Derek Lowe |
Column: In the pipeline The author considers what makes a good looking drug molecule - and how beauty is in the eye of the beholder |
Chemistry World
April 2009
Derek Lowe |
Column: In the pipeline The author considers the problems of addressing drug development out of sequence |
The Motley Fool
June 11, 2007
Brian Lawler |
Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul. |
Chemistry World
January 6, 2014
Mark Peplow |
The morning after the night before David Nutt, a neuropsychopharmacologist at Imperial College London, has an idea with obvious appeal: an alcohol substitute that promises all of the fun of bacchic revelry without the throbbing head and washing-machine stomach that follow. |
The Motley Fool
October 6, 2008
Brian Orelli |
Cardinal Atones for Its Sins The drugmaker gets its licenses to distribute controlled substances reinstated. |
Reason
October 2004
Michael Erard |
Open Secrets How the U.S. government lost the drug war in cyberspace. |
The Motley Fool
April 26, 2007
Brian Lawler |
Brazil's Boneheaded Drug Move Brazil already receives a steep discount on the price that Merck charges it for its HIV compounds. Nevertheless, it wants still lower prices to help reduce the government's costs associated with supplying drugs to those living with HIV/AIDS. |
Chemistry World
June 12, 2013
Maria Burke |
'Scientific censorship' hamstringing psychoactive drug research Legal controls on psychoactive drugs have hindered neuroscience research and the discovery of new treatments for brain disorders in 'one of the most scandalous examples of scientific censorship in modern times', claim researchers. |
Chemistry World
May 18, 2007
Hepeng Jia |
China's Battle with Fake Drugs While China's pharmaceutical industry is experiencing rapid growth, a boom in counterfeit drugs is costing human lives and eroding the public's confidence in medical products. |
Chemistry World
January 18, 2009
Hayley Birch |
Plants reprogrammed to produce potential drugs Plants could one day function as factories for producing anti-cancer drugs, say US scientists. |
The Motley Fool
September 10, 2004
Charly Travers |
Looming Drug Shortages The push for drug re-importation into the U.S. will have consequences abroad. With supply restrictions in place, Canada and the U.K. are at a higher risk of drug shortages if pharmacies in those countries continue to sell drugs to U.S. citizens. |
The Motley Fool
September 12, 2005
M.D. Mitchell |
Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch. |
Chemistry World
December 2009 |
Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs |
American Family Physician
June 1, 2004
Gahlinger |
Club Drugs: MDMA, Gamma-Hydroxybutyrate (GHB), Rohypnol, and Ketamine About club drugs, outcomes of ingestion and treatments after ingestion. |
ONLINE
Jan/Feb 2002
Elaine N. Cheeseman |
IDdb3: Pharmaceutical Intelligence for the Third Millennium Are you looking for many types of drug pipeline information in one place? Interested in locating current pharmaceutical patent, company, or conference information? Do you need quick and easy access to this information? |
Chemistry World
January 15, 2009
Ned Stafford |
Synthetic cannabis mimic found in herbal incense A chemical substance first synthesized in 1995 in a university lab in the US is now being used by young people around the world to legally achieve a marijuana-like high and is causing alarm among health officials in Europe. |
The Motley Fool
December 12, 2007
Brian Lawler |
Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation. |
The Motley Fool
January 31, 2007
Brian Lawler |
FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer. |
Salon.com
July 6, 2000
Ted Oehmke |
The poisoning of suburbia An 18-year-old girl died after taking a pill she thought was ecstasy. Is her death a sign of more tragedies to come? |
Chemistry World
April 2008
Derek Lowe |
Column: In the Pipeline The recent row over antidepressants reminds us how little we know about the brain. |
Bio-IT World
June 17, 2004
John Garvey |
Rational Decisions As companies in the computationally guided rational drug design sector mature, they should be more sure of the boundaries that surround their proprietary technologies. |
Chemistry World
June 2008
Sarah Houlton |
Breaking the rules The author finds out about some chemical tricks that can give a new drug the best possible odds of success |
Chemistry World
July 2008
Kevin Rogers |
What future for small molecule therapy? Pharmaceutical companies overlook bench chemists at their peril |
Chemistry World
April 30, 2014
Emma Stoye |
New Zealand in legal highs U-turn Politicians in New Zealand have decided to ban designer drugs from sale in the country, reversing an earlier decision to approve low risk drugs while new laws are put in place. |
Chemistry World
December 2008 |
Column: In the pipeline I've worked on two drug discovery efforts (one right after the other, as fate would have it) whose final compounds differed by essentially one methyl group from the starting points of each project. |
Chemistry World
May 15, 2009
Katrina Megget |
Tripping over red tape The UK may be moving a step closer to allowing the use of a cannabis-based drug to treat the symptoms of multiple sclerosis |
Chemistry World
June 2007
Derek Lowe |
Opinion: In the Pipeline A medicinal chemist experienced in pre-clinical drug discovery sets the record straight about pharmaceutical patents on traditional medicines. |
Chemistry World
July 13, 2007
Hepeng Jia |
Chinese Legislation to Increase Drug Safety A long-awaited amendment to China's drug registration system is expected to discipline the country's medical sector and boost the pharmaceutical industry. |
| Knowledge@Wharton |
Analyzing Brand-name and Generic Drug Costs in the U.S. and Eight Other Countries A new study comparing average prices for pharmaceuticals in nine countries -- the US, Canada, Chile, France, Germany, Italy, Japan, Mexico and the UK -- shows that average prices are highest in Japan, while prices in other countries are between 6% and 33% lower than prices in the US. |
Chemistry World
September 2008
Derek Lowe |
Column: In the pipeline The author remembers leaving the ivory towers of academe to trade 'unusual and beautiful' for 'useful' |
Reason
January 2002
Jacob Sullum |
Sex, Drugs, and Techno Music Why the rap against Ecstasy has a familiar ring to it |
Chemistry World
October 2008
Derek Lowe |
Column: In the pipeline The author seeks a cure for 'compound bloat' |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
CFO
Kris Frieswick |
Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist... |
Pharmaceutical Executive
February 1, 2006
Ron Feemster |
Gene Logic: Rescue Squad One or two late-stage clinical failures can land promising drug candidates on the shelf. Forever? Maybe not. Gene Logic tests Big Pharma's dead drugs for hundreds of different targets. |
Pharmaceutical Executive
February 1, 2007
Patrick Clinton |
From the Editor: Meaningless A bill requiring the Secretary of Health and Human Services to negotiate Medicare drug prices directly with pharmaceutical manufacturers has a fatal flaw. |
The Motley Fool
December 11, 2006
Michael P. Cecil |
Why Doesn't Buffett Buy Drug Companies? Investors, how do you estimate the amount of money that a drug company, or perhaps more simply one of its drugs, will produce over its lifetime? |
The Motley Fool
March 15, 2007
Brian Lawler |
It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers. |
The Motley Fool
January 22, 2007
Michael P. Cecil |
Will Medicare Negotiate With Drug Companies? One of the bedrock principles of our economic system is that those buying more of a product receive a discount. Wouldn't empowering Medicare to save taxpayers' money be widely embraced as a great idea? But how would pharma investors see it? |
